// App-Quantinova.ai

46 : Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Researchers

Presenter

  • Tim H Brmmendorf

Principal Investigators

  • Dragana Milojkovic

  • Carlo Gambacorti-Passerini

  • Richard E. Clark

  • Philipp D le Coutre

  • Valentn Garcia-Gutirrez

  • Charles Chuah

  • Vamsi Kota

  • Jeffrey H. Lipton

  • Philippe Rousselot

  • Michael J. Mauro

  • Andreas Hochhaus

  • Rafael Hurtado Monroy

  • Eric Leip

  • Simon Purcell

  • Anne Yver

  • Andrea Viqueira

  • Michael W. Deininger

Medical Centers

  • Department of Hematology and Oncology, Center for Integrated Oncology (CIO), Uniklinik RWTH Aachen, Aachen, Germany

  • Department of Hematology and Oncology, Center for Integrated Oncology (CIO), Uniklinik RWTH Aachen, Aachen, Germany

  • Georgia Cancer Center, Augusta University, Augusta, GA

  • Department of Haematology, Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom

  • Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

  • Department of Gastroenterology, University of Liverpool, Liverpool, United Kingdom

  • Charite Universitaetsmedizin Berlin, Medical Oncology, Berlin, Germany

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Department of General Surgery, Singapore General Hospital, Singapore, Singapore

  • Hans Messner Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Centre Hospitalier De Versailles Le Chesnay France

  • Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

  • Klinik für Innere Medizin II, Jena, Germany

  • Hematology Department, Hospital Angeles del Pedregal, Mexico City, Mexico

  • Pfizer Inc., Cambridge, MA

  • Pfizer Ltd, London, GBR

  • Pfizer Inc., Paris, France

  • Pfizer Spain, Madrid, Spain

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Locations

  • Germany

  • United States

  • United Kingdom

  • Italy

  • Spain

  • Singapore

  • Canada

  • France

  • Mexico

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Ischemia Modified Albumin

Drug/Treatment

  • Bosutinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT02130557

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved